Ethos Treatment Management (3.0); Ethos Treatment Planning (2.0)

The Ethos Treatment Management 3.0 and Ethos Treatment Planning 2.0 systems are advanced software tools designed to streamline and enhance radiation therapy workflows through sophisticated treatment planning, management, and monitoring capabilities. They leverage AI-driven deep learning for automated anatomical contouring, an enhanced optimization engine for plan generation, and support for adaptive radiotherapy techniques, aiming to improve precision and efficiency in patient treatment.

Ethos Treatment Management 3.0 is a software product designed to assist radiation therapy professionals in managing and monitoring patient treatment plans and sessions. It enables physicians to define radiation treatment intent, review and approve candidate plans, and track treatment progress, operating in conjunction with a treatment planning system. Ethos Treatment Planning 2.0 is a standalone software application for generating and modifying radiation therapy treatment plans, supporting both conventional and adaptive radiotherapy strategies where plans are adjusted to the patient's current anatomy for malignant or benign diseases requiring radiation therapy. These updated versions incorporate significant technological advancements, including high-fidelity mode support and AI-driven segmentation using deep learning algorithms for automated anatomical contouring based on static convolutional neural networks. Ethos Treatment Planning 2.0 further introduces an enhanced Intelligent Optimizer Engine, a new Beam Geometry Optimizer, and direct CBCT dose calculation capabilities with HyperSight CBCT. The AI models were trained on a diverse dataset of CT and CBCT scans and validated using quantitative metrics like the DICE similarity coefficient and qualitative expert reviews confirming high accuracy (minor or no adjustments needed in over 80% of test cases). Both systems underwent comprehensive design verification and validation according to industry standards, demonstrating they perform as intended and meet essential performance requirements, though the software is designated with a "major" level of concern due to its critical role in patient treatment.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of the AI segmentation models in Ethos 3.0/2.0 vary across different anatomical sites and imaging modalities (CT vs. CBCT), particularly for organs with significant inter-fractional variation?; What specific quantitative improvements in plan quality or efficiency (e.g., planning time, dose conformity) are achieved with the enhanced Intelligent Optimizer Engine and new Beam Geometry Optimizer in Ethos Treatment Planning 2.0 compared to previous versions?; Given the "major" level of concern for the software, what are the most critical failure modes identified during risk management, and what specific mitigation strategies are implemented within the software design to address them?; How does the direct CBCT dose calculation capability using HyperSight CBCT in Ethos Treatment Planning 2.0 account for potential variations in Hounsfield Unit accuracy in CBCT images compared to standard CT simulation scans?; What is the anticipated learning curve for clinicians and physicists transitioning to Ethos 3.0/2.0, particularly concerning the new AI features and adaptive workflow, and what training or support is recommended for effective implementation?